Table 5:
Secondary outcomes and adverse effects during prior month reported at 3 mo and 6 mo
| Variable | No nasal irrigation | Nasal irrigation | No steam inhalation | Steam inhalation |
|---|---|---|---|---|
| Reported at 3 mo | ||||
| Headache, % | 81.7 | 72.0 | 80.4 | 73.1 |
| Univariate RR (95% CI) | 1.00 | 0.88 (0.81 to 0.95) | 1.00 | 0.90 (0.83 to 0.98) |
| Adjusted RR (95% CI) | 1.00 | 0.88 (0.81 to 0.96) | 1.00 | 0.91 (0.84 to 0.99) |
| Adverse effects,* % | 65.6 | 64.2 | 66.8 | 62.9 |
| Univariate RR (95% CI) | 1.00 | 0.98 (0.88 to 1.10) | 1.00 | 0.94 (0.83 to 1.05) |
| Adjusted RR (95% CI) | 1.00 | 0.98 (0.88 to 1.09) | 1.00 | 0.92 (0.82 to 1.03) |
| Use of OTC treatment,† % | 67.4 | 60.0 | 64.3 | 62.9 |
| Univariate RR (95% CI) | 1.00 | 0.89 (0.80 to 1.00) | 1.00 | 0.98 (0.87 to 1.10) |
| Adjusted RR (95% CI) | 1.00 | 0.90 (0.81 to 1.00) | 1.00 | 0.99 (0.89 to 1.11) |
| Reported at 6 mo | ||||
| Headache, % | 79.8 | 73.9 | 77.3 | 76.2 |
| Univariate RR (95% CI) | 1.00 | 0.93 (0.85 to 1.01) | 1.00 | 0.98 (0.90 to 1.07) |
| Adjusted RR (95% CI) | 1.00 | 0.93 (0.85 to 1.01) | 1.00 | 0.99 (0.91 to 1.08) |
| Adverse effects,* % | 66.7 | 60.6 | 63.9 | 63.3 |
| Univariate RR (95% CI) | 1.00 | 0.91 (0.81 to 1.02) | 1.00 | 0.99 (0.87 to 1.13) |
| Adjusted RR (95% CI) | 1.00 | 0.90 (0.80 to 1.01) | 1.00 | 0.98 (0.86 to 1.12) |
| Use of OTC treatment,† % | 68.0 | 59.4 | 64.8 | 62.4 |
| Univariate RR (95% CI) | 1.00 | 0.87 (0.78 to 0.98) | 1.00 | 0.96 (0.85 to 1.08) |
| Adjusted RR (95% CI) | 1.00 | 0.87 (0.78 to 0.97) | 1.00 | 0.95 (0.85 to 1.07) |
Note: CI = confidence interval, OTC = over the counter, RR = risk ratio.
*
Includes nosebleeds, nasal burning or stinging, soreness.
†
Participants were asked at 3 mo and 6 mo whether they had used an acetylsalicylic acid oral rinse, benzydamine hydrochloride oral rinse, cough medicine, mentholated topical ointment, echinacea, lozenges or nasal sprays in the preceding month.